Future Of British Business
GSK Lifts Profit Forecast, Boosted By World’s First RSV Vaccine
- Drug company cites ‘outstanding’ US demand for Arexvy shot
- UK company’s vaccines unit is now the best performing division
This article is for subscribers only.
GSK Plc raised its guidance for the second time this year as demand surges for its breakthrough vaccine to prevent a common respiratory virus in adults.
The UK pharmaceutical company now expects sales to increase by as much as 13% and adjusted earnings per share to rise as much as 20% this fiscal year. The high end of each range is 3 percentage points above previous forecasts.